SESSION R.A. II (President and CEO) sold 4.6% of their position (434.62K shares) of TAYSHA GENE THERAPIES, INC. on the open market
Open‑market sale worth $307.8K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 6/22/2023ACC: 0000899243-23-016232
DirectorOfficer10% Owner· President and CEO
Since Sep 2020
-434.62K
Net shares
Net seller
$307.8K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
434.62K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−295.65K
Price / share
$0.71
Trade value
$210.21K
% of position
3.1%
6/20/2023
9.42M→9.13M
Common Stock
Direct
Shares
−138.96K
Price / share
$0.70
Trade value
$97.63K
% of position
1.5%
6/21/2023
9.13M→8.99M
Total
Net shares
−434.62K
Net value
-$307.84K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/20/2023 | S · Sale | −295.65K | $0.71 | $210.21K | 3.1% | 9.42M | 9.13M |
| Common Stock Direct | 6/21/2023 | S · Sale | −138.96K | $0.70 | $97.63K | 1.5% | 9.13M | 8.99M |
| Total | −434.62K | -$307.84K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock
IndirectShares owned141.09K
Common Stock
IndirectShares owned141.09K
Total
282.18K indirect282.18K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 141.09K | Indirect |
| Common Stock | 141.09K | Indirect |
| Total | 282.18K | 282.18K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported